1. Scrip
  2. >>Therapy Areas

Longer Intervals OK With ViiV's Injectable Anti-HIV Regimen

 
• By John Davis

Topline results from the Phase III ATLAS-2M study indicate that injections every two months of ViiV/Janssen’s two-drug anti-HIV regimen are non-inferior to a once-monthly injectable regimen.  

Consultation
Avoiding constant reminders of ill-health may benefit some patients • Source: Shutterstock

ViiV Healthcare /Janssen Pharmaceutical Cos.’s long-acting injectable anti-HIV regimen of cabotegravir and rilpivirine, administered every two months, has met its primary endpoint in the global Phase III ATLAS-2M study, underlining its potential role as a more convenient therapy for patients.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas